Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
Status:
Completed
Trial end date:
2018-12-03
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, placebo controlled, blinded, parallel two arm, multicentre
trial that will compare rivaroxaban 10mg daily with placebo in patients with symptomatic leg
Superficial Vein Thrombosis (> or = 5cm) that otherwise would not initially be treated with
anticoagulant therapy.